Bridion Sugammadex Sodium Injection

1. Indications and Usage
Reversal of Neuromuscular Blockade: Indicated for the reversal of rocuronium- or vecuronium-induced neuromuscular blockade in adult patients.
Pediatric Use: In children and adolescents (2 to 17 years), it is indicated only for routine reversal of rocuronium-induced neuromuscular blockade.
2. Dosage and Administration
Route of Administration: Intravenous bolus injection ONLY. The injection must be administered over 10 seconds into an existing intravenous line.
Dosing Based on Depth:
Routine Reversal: When spontaneous recovery has reached at least 2 post-tetanic counts (PTC) or the second twitch (T2) of the train-of-four (TOF) reappears, the recommended dose is 2 mg/kg.
Deep Reversal: When the neuromuscular blockade has recovered to at least 1 to 2 PTC, the recommended dose is 4 mg/kg.
Redosing: If postoperative neuromuscular blockade recurs after the initial dose, a single redose of 4 mg/kg is recommended.
3. Mechanism of Action
Encapsulation: Sugammadex is a modified cyclodextrin that selectively and reversibly binds to rocuronium or vecuronium in the plasma.
Rapid Clearance: It forms a stable, water-soluble 1:1 complex that is rapidly excreted unchanged by the kidneys, effectively removing the neuromuscular blocker from the neuromuscular junction and restoring muscle strength.
4. Safety and Warnings
Hypersensitivity: Anaphylactic or anaphylactoid reactions have been reported. The drug is contraindicated in patients with known severe hypersensitivity to sugammadex or its excipients.
Brachial Plexus Injury: Prolonged or deep compression of the arm during surgery may increase the risk of brachial plexus injury due to the rapid onset of muscle strength, potentially leading to movement before the patient is fully awake.
Renal Impairment: In patients with severe renal impairment (creatinine clearance <30 mL/min), including those on dialysis, the drug is not recommended due to significantly reduced clearance and potential accumulation.
Recurrent Blockade: Postoperative neuromuscular blockade may recur, especially after high doses of rocuronium or vecuronium.
5. Adverse Reactions and Clinical Research
Most Common Adverse Reactions: Nausea, vomiting, pyrexia, and bradycardia.
Clinical Research Highlights: Clinical trials have demonstrated that sugammadex provides rapid and reliable reversal of neuromuscular blockade with a lower incidence of residual blockade compared to traditional reversal agents.
6. Drug Interactions
Hormonal Contraceptives: Sugammadex can bind to steroid hormones, reducing the efficacy of hormonal contraceptives (e.g., levonorgestrel, ethinylestradiol). Alternative non-hormonal contraception is recommended during and for 7 days after administration.
Ciclosporin: Sugammadex may significantly reduce cyclosporine exposure and should not be administered within 18 hours of cyclosporine.
7. Pharmaceutical Information
Chemical Composition: Active Ingredient: Sugammadex sodium.
Appearance: Colorless to slightly yellow clear solution.
Packaging: Available in various strengths (e.g., 100 mg/mL).
Storage: Store at controlled room temperature; do not freeze.